Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
17 Julio 2023 - 7:00AM
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in
minimally invasive treatments for lung disease, today announced
that it will release financial results for the second quarter of
2023 after the close of trading on Wednesday, August 2, 2023.
Company management will host a conference call to discuss financial
results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be
available on the “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/.
About Pulmonx
CorporationPulmonx Corporation (Nasdaq: LUNG) is a global
leader in minimally invasive treatments for severe lung disease.
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary
Assessment System and StratX® Lung Analysis Platform are designed
to assess and treat patients with severe emphysema/COPD who despite
medical management are still profoundly symptomatic. Pulmonx
received FDA pre-market approval to commercialize the Zephyr Valve
following its designation as a “breakthrough device.” The Zephyr
Valve is commercially available in more than 25 countries, with
over 100,000 valves used to treat more than 25,000 patients. For
more information on the Zephyr Valves, please visit
https://uspatients.pulmonx.com/. For more information on the
company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are
registered trademarks of Pulmonx Corporation.
ContactBrian JohnstonGilmartin
Groupinvestors@pulmonx.com
Pulmonx (NASDAQ:LUNG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Pulmonx (NASDAQ:LUNG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024